BFRI
Biofrontera Inc. (NASDAQ)
Healthcare — Drug Manufacturers - Specialty & Generic
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
None
2 analysts
$1.01
+$0.06 (+6.77%)
Target:
$5.88
(481.7%)
Sign in to add BFRI to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $12.93M |
| P/E Ratio (TTM) | - |
| Forward P/E | 3.16 |
| EPS (TTM) | $-0.98 |
| Dividend Yield | - |
| Profit Margin | -25.66% |
| Revenue Growth | 17.40% |
| ROE | -339.04% |
| Debt/Equity | 127.25 |
| Recommendation | None |
| Analyst Target | $5.88 |
| Analysts | 2 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 60.8 |
| Beta | 0.85 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $1.19 |
| 52-Week Low | $0.56 |
| 50-Day Avg | $0.98 |
| 200-Day Avg | $0.92 |
| Avg Volume | 216.4K |
| Volume | 240.2K |
Performance Analysis
BULLISHBFRI shows predominantly bullish signals based on its fundamentals and technicals.
+
Showing strength at 72% of its 52-week range.
+
RSI at 60.8 shows positive momentum.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
~
Modest revenue growth of 17.4% year-over-year.
-
Operating at a loss with -25.7% margin.
~
Wall Street consensus is "none" from 2 analysts.
+
Average analyst target of $5.88 implies 481.7% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 12:59 UTC
Back to Screener Export Report